DNLI

Denali is a clinical-stage neuroscience biotech with no approved products and, per the 10-K Risk Factors, explicitly warns it 'may never' generate product revenue. The numbers confirm a pure cash-burn profile: FY2025 revenue was $0.00 (down from $331M in FY2023 when collaboration milestones flowed), operating loss widened to -$555M, net loss deepened to -$513M (YoY worse by 21%), and operating cash flow was -$413M. With only $205M cash on hand against a $413M annual burn, the runway is roughly six months at the operating-cash-flow rate before further dilution — and shares are already up 9.2% YoY, against a -$2.05B accumulated deficit that grew 33% in the year. Equity is being consumed: stockholders' equity fell 17.6% to $1.01B and ROE is -50.6%.

The Risk Factors are unusually candid about the binary nature here: management flags concentration on 'neurodegenerative and lysosomal storage diseases, fields that have seen limited success in drug development,' heavy reliance on its TV (transport vehicle) platform, dependence on third-party CROs and collaboration partners, and the lengthy/unpredictable FDA-EMA approval path. The MD&A reinforces that revenue, when it appears, is collaboration-driven and judgment-laden — not recurring product sales — which is why FY2024-2025 revenue collapsed to zero after the FY2023 milestone bump. There is no margin trend to analyze because there is no business yet; there is only a research budget ($419M R&D, +5.6% YoY) being funded out of a shrinking treasury.